BeOne Medicines Reports Sustained Survival Benefit for Tevimbra Combination in Phase 3 Cancer Trial

BeOne Medicines announced results from a Phase 3 clinical trial of Tevimbra combined with Ziihera and chemotherapy for gastroesophageal adenocarcinoma. The trial showed a median overall survival of 27 months, a four-month increase compared to the Ziihera and chemotherapy combination alone. Additionally, median progression-free survival improved to 12.7 months, with no new safety concerns reported.